首页> 外文期刊>Journal of thrombosis and thrombolysis >Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there
【24h】

Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there

机译:固定剂量4因素凝血酶凝血酶浓缩物:如果我们不知道如何到达那里,我们不知道我们要去哪里

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

4-Factor Prothrombin Complex Concentrate (4F-PCC) is the standard-of-care intervention in patients with major bleeding taking oral vitamin K antagonists. Despite growing clinical experience with 4-FPCC, the optimal dosing strategy remains unclear. In balancing efficacy, safety, and cost of this treatment, many institutions have adopted a low, fixed-dose regimen, with average doses lower than that in the package insert. The fixed-dose 4F-PCC strategy is supported by the available observational studies and case reports; however, the current body of literature is highly heterogenous. The purpose of this narrative review is to address the advantages and shortcomings with clinical use of fixed-dose 4F-PCC, as well as limitations of the available literature. The heterogeneity of the current literature should guide future studies to support or refute this potentially life-saving intervention.
机译:4因素凝血酶原浓缩物(4F-PCC)是服用口服维生素K拮抗剂的主要出血的患者的标准干预。 尽管具有4-FPCC的临床经验日益增长,但最佳的计量策略仍然不清楚。 在平衡效力,安全性和这种治疗的成本方面,许多机构采用了低固定剂量的方案,平均剂量低于包装插入物中的剂量。 可用的观察研究和案例报告支持固定剂量4F-PCC策略; 然而,目前的文献体是高度异质的。 该叙事审查的目的是解决具有固定剂量4F-PCC的临床应用的优势和缺点,以及可用文献的限制。 目前文献的异质性应引导未来的研究支持或反驳这种潜在的救生干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号